Safe Nuclear Factor-kappa B Inhibitor for Cachexia Management

악액질 완화를 위한 안전한 Nuclear Factor-kappa B 전사인자 제어 물질 발굴

  • Park, Jeong-Soo (Department of Biochemistry, Dankook University College of Medicine)
  • 박정수 (단국대학교 의과대학 생화학교실)
  • Received : 2012.07.02
  • Accepted : 2012.07.19
  • Published : 2012.08.31


Purpose: Cachexia is a complex metabolic syndrome associated with wasting of skeletal muscle which contributes to nearly one-third of all cancer deaths. Cachexia lowers the frequency of response to chemotherapy and radiation and ultimately can impact survival as well as quality of life during treatment. NF-kappa B is one of the most important molecular mediators of cachexia. In this study, therefore, possible candidates for inhibitors of NF-kappa B were searched. Methods: Amino acids that regulate cellular redox potential by adjusting the level of NAD/NADH ratio, such as aspartate, pyruvate, and isocitrate were selected. Results: Pyruvate effectively inhibited luciferase activity in TNF-stimulated 293T cells transfect with an NF-kB dependent luciferase reporter vector. Pyruvate also showed protective effect on muscle atrophy of differentiated C2C12 myocyte induced by TNF/IFN. Conclusion: We might be able to develop the nutritional management strategy for cancer cachexia patients with pyruvate supplementation.


Supported by : 단국대학교


  1. Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S., et al. (2004). Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. Journal of Clinical Investigation, 114, 370-378.
  2. Andreyev, H. J., Norman, A. R., Oates, J., & Cunningham, D. (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer, 34, 503-509.
  3. Argiles, J. M., & Lopez-Soriano, F. J. (1999). The role of cytokines in cancer cachexia. Medical Research Reviews, 19, 223-248.<223::AID-MED3>3.0.CO;2-N
  4. Barber, M. D., Ross, J. A., & Fearon, K. C. (1999). Cancer cachexia. Surgical Oncology, 8, 133-141.
  5. Barron, J. T., Gu, L., & Parrillo, J. E. (1998). Malate-aspartate shuttle, cytoplasmic NA DH redox potential, and energetics in vascular smooth muscle. Journal of Molecular and Cellular Cardiology, 30, 1571-1579.
  6. Beg, A. A., & Baldwin, A. S. (1993). The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes & Development, 7, 2064-2070.
  7. Choi, S. G. (2011). Recent advances in cancer cachexia. Journal of Korean Oncology Nursing, 11, 20-25.
  8. Decramer, M., Rutten-van Molken, M., Dekhuijzen, P. N., Troosters, T., van Herwa-arden, C., Pellegrino, R., et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cose-utility study, BRONCUS): a randomized placebo-controlled trial. Lancet, 365, 1552-1560.
  9. Evans, W. J., Morley, J. E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., et al. (2008). Cachexia: A new definition. Clinical Nutrition, 27, 793-799.
  10. Fink, M. P. (2008). Ethyl pyruvate. Current Opinion in Anesthesiology, 21, 160-167.
  11. Ginn-Pease, M. E., & Whisler, R. L. (1998). Redox signals and NF-kappaB activation in T cells. Free Radical Biology & Medicine, 25, 346-361.
  12. Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011). Nutritional interventions for cancer-induced cachexia. Current Problems in Cancer, 35(2), 58-90.
  13. Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C. Y., & Baldwin, A. S. Jr. (2000). NF-kappaB -induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science, 289, 2363-2366.
  14. Han, Y., Englert, J. A., Yang, R., Delude, R. L., & Fink, M. P. (2005). Ethyl pyruvate inhibits nuclear factor kappaB-dependent signaling by directly targeting p65. Journal of Pharmacology and Experimental ‘erapeutics, 312, 1097-1105.
  15. Hopkinson, J. B., Wright, D. N., McDonald, J. W., & Corner, J. L. (2006). The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. Journal of Pain and Symptom Management, 32, 322-331.
  16. Im, J. H., & Choe, M. A. (2002). Effect of exercise during acute stage of stroke on affected and unaffected hindlimb muscle mass of cerebral ischemic rat. Journal of Korean Biological Nursing Science, 4, 51-69.
  17. Kawamura, I., Morishita, R., Tomita, N., Lacey, E., Aketa, M., Tsujimoto, S., et al. (1999). Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene ‘erapy, 6, 91-97.
  18. Kaileh, M., & Sen, R. (2012). NF-kB function in B lymphocytes. Immunological Reviews, 246, 254-271.
  19. Larkin, M. (1998). Thwarting the dwindling progression of cachexia. Lancet, 351, 1336.
  20. Li, L., Thomas, M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004). A small molecule Smac mimic potentiates TRAIL- and TNF-$\alpha$-mediated cell death. Science, 305, 1471-1474.
  21. MacDonald, N., Easson, A. M., Mazurak, V. C., Dunn, G. P., & Baracos, V. E. (2003). Understanding and managing cancer cachexia. Journal of American College of Surgeons, 197, 143-161.
  22. Massudi, H., Grant, R., Guillemin, G. J., & Braidy, N. (2012). NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Report, 17, 28-46.
  23. O'Gorman, P., McMillan, D. C., & McArdle, C. S. (1998). Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutrition and Cancer, 32, 76-80.
  24. Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., et al. (1987). Tumors secreting human TNF/cachectin induce cachexia in mice. Cell, 50, 555-563.
  25. Park, Y. C., & Park, S. C. (1995). Reduction of oxidative stress by aspartate in the ethanol-perfused rat liver tissues. Korean Journal of Biochemistry, 27, 165-169.
  26. Park, Y. C., Oh, S. I., Park, Y. H., & Park, S. C. (1997). Modulation by aspartate of ischemia/reperfusion-induced oxidative stress in rat liver. Experimental Molecular Medicine, 29, 19-23.
  27. Schwartz, S. A., Hernandez, A., & Mark Evers, B. (1999). The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surgical Oncology, 8, 143-153.
  28. Sen, C. K., & Packer, L. (1996). Antioxidant and redox regulation of gene transcription. ‘The FASEB Journal, 10, 709-720.
  29. Staal, F. J., Roederer, M., Herzenberg, L. A., & Herzenberg, L. A. (1990). Intracellular thiols regulate activation of nuclear factor kB and transcription of human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America, 87, 9943-9947.
  30. Tracey, K. J., & Cerami, A. (1994). Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annual Review of Medicine, 45, 491-503.
  31. van Eys, J. (1985). Nutrition and cancer: physiological interrelationships. Annual Review of Nutrition, 5, 435-461.
  32. van Zandwijk, N., Dalesio, O., Pastorino, U., & de Vries, N. (2000). EUROSCAN, a randomized trial of Vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. Journal of National Cancer Institute, 92, 977-986.
  33. Varma, S.D., Devamanoharan, P. S., & Ali, A. H. (1998). Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radical Research, 28, 131-135.
  34. Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003). Molecular mechanisms of N-acetylcysteine actions. Cellular and Molecular Life Sciences, 60, 6-20.